Insurers, pension funds, and Restasis users accusing Allergan of conspiring to delay generic competition for the dry eye drug convinced a Brooklyn federal judge to grant them class action status, reported Bloomberg.
Although the class of “end payer plaintiffs” likely contains some “brand loyalists” who weren’t harmed by the company’s alleged sham litigation scheme, the plaintiffs’ expert adequately demonstrated that the number was “de minimis,” Judge Nina Gershon wrote Tuesday, May 5.
The ruling comes about 10 weeks after Allergan agreed to settle parallel claims by drug distributors for US$51 million.
The sprawling antitrust suit accuses Allergan of “inundating” the Food and Drug Administration (FDA) with bad faith “citizen petitions” challenging the safety of Restasis generics proposed by other drugmakers. After the FDA rejected the petitions, Allergan allegedly launched bogus lawsuits claiming its would-be competitors infringed patents it had intentionally mischaracterized to regulators.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Plaintiffs Seek Communications In Antitrust Case Against Pioneer
May 9, 2024 by
CPI
UK Government Approves Vodafone-Hutchison Merger
May 9, 2024 by
CPI
Senate Majority Leader Announces Plan for AI Regulation Framework
May 9, 2024 by
CPI
BBVA Initiates Aggressive Takeover Bid for Sabadell
May 9, 2024 by
CPI
TikTok to Label AI-Generated Content Amid Election Interference Concerns
May 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI